NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

X4 Pharmaceuticals Inc (NASDAQ: XFOR)

 
XFOR Technical Analysis
5
As on 28th Apr 2025 XFOR SHARE Price closed @ 5.34 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.87 & Strong Buy for SHORT-TERM with Stoploss of 0.78 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

XFORSHARE Price

Open 5.54 Change Price %
High 6.63 1 Day 5.15 2710.53
Low 5.00 1 Week 5.14 2570.00
Close 5.34 1 Month 5.00 1470.59
Volume 284386 1 Year 4.60 621.62
52 Week High 1.47 | 52 Week Low 0.19
 
NASDAQ USA Most Active Stocks
AGMH 0.13 160.00%
AMRS 0.14 100.00%
DGLY 0.03 0.00%
GNLN 0.01 0.00%
PTPI 0.06 20.00%
PLUG 1.02 25.93%
NVDA 108.73 -2.05%
TSLA 285.88 0.33%
WW 0.41 2.50%
LMDX 0.02 0.00%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
XFOR 5.34 2710.53%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
ADXS 0.10 233.33%
NDRAW 0.03 200.00%
AGMH 0.13 160.00%
GLSPT 33.43 138.62%
BIOC 0.07 133.33%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
BPTH 0.21 -66.67%
TFFP 0.06 -62.50%
ATMH 0.04 -60.00%
MILEW 0.06 -53.85%
VINC 0.05 -50.00%
 
 
XFOR
Daily Charts
XFOR
Intraday Charts
Whats New @
Bazaartrend
XFOR
Free Analysis
 
XFOR Important Levels Intraday
RESISTANCE8.48
RESISTANCE7.47
RESISTANCE6.85
RESISTANCE6.23
SUPPORT4.45
SUPPORT3.83
SUPPORT3.21
SUPPORT2.20
 
XFOR Forecast April 2025
4th UP Forecast5.86
3rd UP Forecast5.69
2nd UP Forecast5.59
1st UP Forecast5.49
1st DOWN Forecast5.19
2nd DOWN Forecast5.09
3rd DOWN Forecast4.99
4th DOWN Forecast4.82
 
XFOR Weekly Forecast
4th UP Forecast5.61
3rd UP Forecast5.52
2nd UP Forecast5.47
1st UP Forecast5.42
1st DOWN Forecast5.26
2nd DOWN Forecast5.21
3rd DOWN Forecast5.16
4th DOWN Forecast5.07
 
XFOR Forecast2025
4th UP Forecast17.79
3rd UP Forecast13.8
2nd UP Forecast11.33
1st UP Forecast8.86
1st DOWN Forecast1.82
2nd DOWN Forecast-0.65
3rd DOWN Forecast-3.12
4th DOWN Forecast-7.11
 
 
XFOR Other Details
Segment EQ
Market Capital 119536192.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
XFOR Address
XFOR
 
XFOR Latest News
 
Your Comments and Response on X4 Pharmaceuticals Inc
 
XFOR Business Profile
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Address: 61 North Beacon Street, Boston, MA, United States, 02134
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service